Publications

Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ. Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. NPJ breast cancer. 2025. PMID: 41271741


Michelle Melisko, MD

Corti C, Rugo HS, Tolaney SM. Erratum: Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2025. PMID: 41270251


Hope Rugo, MD

Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ. Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. NPJ breast cancer. 2025. PMID: 41271741


Pamela Munster, MD

Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ. Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. NPJ breast cancer. 2025. PMID: 41271741


Mark Moasser, MD

Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ. Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. NPJ breast cancer. 2025. PMID: 41271741


Lawrence Fong, MD

Vogl UM, Merler S, Angrisani A, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small EJ, Smith MR, Sweeney CJ, Tombal B, Zilli T, Herrmann K, Omlin A, Gillessen S, APCCC 2024 expert panel. A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024. European journal of cancer (Oxford, England : 1990). 2025. PMID: 41407614


Eric Small, MD

Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ. Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. NPJ breast cancer. 2025. PMID: 41271741


Melanie Majure, MD

Pithadia DJ, Heskel MJ, Shotayev A, Davda S, Durand R, Cooke D, Czechowicz J, Lesh M, Cornett P, Shimano KA, Mathes EF, Frieden IJ, Apsel Winger B. Alpelisib, a PI3Kα inhibitor, effectively treats vascular anomalies with diverse genotypes and phenotypes. Blood vessels, thrombosis & hemostasis. 2025. PMID: 41623364


Patricia Cornett, MD

Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ. Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. NPJ breast cancer. 2025. PMID: 41271741


Hope Rugo, MD

Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ. Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. NPJ breast cancer. 2025. PMID: 41271741


Jo Chien, MD

Celsa C, Pressiani T, Nishida N, Chamseddine SM, Arvind A, Li M, Fortuny M, Khaled NB, Iavarone M, Toyoda H, Rapposelli IG, Casadei-Gardini A, Vivaldi C, Ulahannan S, Andanamala H, Scheiner B, Pinter M, Orlandi E, Fulgenzi CAM, Manfredi GF, Lombardi P, D'Alessio A, Stefanini B, Villani R, Ponziani FR, Stella L, Carminati O, Ricci AD, Gonzalez M, Sparacino A, Di Maria G, Vaccaro M, Cabibbo G, Cammà C, Reig M, Kelley RK, Singal AG, Kaseb AO, Kudo M, Rimassa L, Pinato DJ. Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study. JHEP reports : innovation in hepatology. 2025. PMID: 41675370


Robin Kate ("Katie") Kelley, MD

Suryawanshi RK, Jaishankar P, Correy GJ, Rachman MM, O'Leary PC, Taha TY, Matsui Y, Zapatero-Belinchón FJ, McCavitt-Malvido M, Doruk YU, Stevens MGV, Diolaiti ME, Jogalekar MP, Chen H, Richards AL, Kongpracha P, Bali S, Montano M, Rosecrans J, Matthay M, Togo T, Gonciarz RL, Gopalkrishnan S, Neitz RJ, Krogan NJ, Swaney DL, Shoichet BK, Ott M, Renslo AR, Ashworth A, Fraser JS. The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2. eLife. 2025. PMID: 41258893


Alan Ashworth, PhD

Lin Z, Ngo W, Chou YT, Wu H, Susa KJ, Jun YW, Bivona TG, Doudna JA, Wells JA. Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap. Nature chemical biology. 2025. PMID: 41254216


Trever Bivona, MD, PhD

Lin C, Hadfield MJ, Santopietro A, Lagos G, Cheng L, El-Deiry WS, Aggarwal R, Mega A, Hyams E, Carneiro BA. The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer. NPJ precision oncology. 2025. PMID: 41238753


Rahul Aggarwal, MD

Mulima G, Mody GN, Kaimila B, Salima A, Williams B, Paciorek A, Zhang L, Charles A, Westmoreland KD, Van Loon K, Buckle GC. Treatment Outcomes of Esophageal Cancer in Malawi: An Analysis of Overall Survival and Patient-Reported Outcomes. JCO global oncology. 2025. PMID: 41232057


Li Zhang, PhD

Mulima G, Mody GN, Kaimila B, Salima A, Williams B, Paciorek A, Zhang L, Charles A, Westmoreland KD, Van Loon K, Buckle GC. Treatment Outcomes of Esophageal Cancer in Malawi: An Analysis of Overall Survival and Patient-Reported Outcomes. JCO global oncology. 2025. PMID: 41232057


Katherine Van Loon, MD, MPH

Mulima G, Mody GN, Kaimila B, Salima A, Williams B, Paciorek A, Zhang L, Charles A, Westmoreland KD, Van Loon K, Buckle GC. Treatment Outcomes of Esophageal Cancer in Malawi: An Analysis of Overall Survival and Patient-Reported Outcomes. JCO global oncology. 2025. PMID: 41232057


Geoffrey Buckle, MD, MPH

Du J, Wijayaratna UN, Wang X, Fung JP, Huang B, Farzaneh F, Kohn DB, Combes AJ, Gaensler KML. TriLeukeVax: A CD80/IL-15/IL-15Rα Expressing Autologous AML Cell Vaccine Elicits Robust Anti-Leukemic Cytolytic Activity. bioRxiv : the preprint server for biology. 2025. PMID: 41279544


Karin Gaensler, MD

Li Y, Qiu X, Sandusky Z, Tagliaferri K, Li R, Yang X, Zhang T, Liu S, Yan P, Lu F, Jones M, Xiao T, Li W, Goldman S, Cui J, Polyak K, Liu XS, Long HW, Gregory RI, Adelman K, Rosenbluth JM, Brown M. METTL3-dependent m6A RNA methylation suppresses aberrant mammary epithelial differentiation and neoplastic transformation. Proceedings of the National Academy of Sciences of the United States of America. 2025. PMID: 41218124


Jennifer Rosenbluth, MD, PhD

Tolaney SM, Sonpavde GP, Tarantino P, Lustberg MB, Rugo HS. Clinical perspective on management of key adverse events with sacituzumab govitecan. The oncologist. 2025. PMID: 41006069


Hope Rugo, MD